F S&P 500
5,210.00 -2.75 (-0.05%) F Dow Jones
39,123.00 -72.00 (-0.18%) F Nasdaq
18,185.50 -1.00 (-0.01%) E-mini Russell 2000 Index Futur
2,067.00 +2.20 (+0.11%) Petróleo
79.66 +0.67 (+0.85%) Oro
2,334.50 +12.20 (+0.53%)
Theratechnologies Inc. (THTX)
Antes de la apertura del mercado:
Theratechnologies Inc.
2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
514 336 7800
https://www.theratech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 103
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Paul Lévesque | President, CEO & Director | 1.18M | N/D | 1964 |
| Mr. Philippe Dubuc M.B.A., MBA | Senior VP & CFO | 432.31k | N/D | 1967 |
| Mr. Jocelyn Lafond L.L.M., LL.B. | General Counsel & Corporate Secretary | 316.29k | N/D | 1968 |
| Dr. Christian Marsolais Ph.D. | Senior VP & Chief Medical Officer | 434.61k | N/D | 1963 |
| Mr. John Leasure | Global Commercial Officer | 420.91k | N/D | 1965 |
| Hon. Andre Dupras M.Sc. | Vice President of Human Resources | N/D | N/D | 1964 |
Descripción
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Theratechnologies Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 10; Junta: 3; Derechos del accionista: 7; Compensación: 8.
